CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
Aug. 19, 2022—Abbott announced that a study published in Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how a person will recover from traumatic brain injury (TBI) (Korley FK, et al. Lancet Neurol. 2022;21[9]:803–813).
Researchers measured levels of glial fibrillary acidic protein (GFAP) and ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) in blood plasma within 24 hours of injury. Abbott’s FDA-cleared i-Stat TBI Plasma test and the company’s Architect instrument measured the markers using research prototype assays. Results are available about 15 minutes after inserting a plasma sample in the test i-Stat cartridge.
Pages: 1 2